NCT05246514 - A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 13, 2022

Primary Completion Date

September 23, 2023

Study Completion Date

March 16, 2026

Conditions

HER2-mutant Non-Small Cell Lung Cancer

Interventions

DRUG

Trastuzumab deruxtecan

administered as an IV infusion

Trial Locations (28)

100142

Research Site, Beijing

100191

Research Site, Beijing

110042

Research Site, Shenyang

130000

Research Site, Changchun

133500

Research Site, Hefei

150081

Research Site, Harbin

200025

Research Site, Shanghai

200032

Research Site, Shanghai

210029

Research Site, Nanjing

225001

Research Site, Yangzhou

230601

Research Site, Hefei

276000

Research Site, Linyi

310020

Research Site, Hangzhou

310022

Research Site, Hangzhou

361003

Research Site, Xiamen

400030

Research Site, Chongqing

410008

Research Site, Changsha

410013

Research Site, Changsha

430022

Research Site, Wuhan

430060

Research Site, Wuhan

450000

Research Site, Zhengzhou

510080

Research Site, Guangzhou

510515

Research Site, Guangzhou

518020

Research Site, Shenzhen

610041

Research Site, Chengdu

710061

Research Site, Xi'an

071000

Research Site, Baoding

Unknown

Research Site, Shandong